American Academy of Optometry – Keratoconus Roundtable
October 25, 2019
Dr. John Gelles is delighted to serve as a panelist, along with Dr. Renee Reeder and Dr. Randall Sakamoto (Dr. Barr – moderator) during the keratoconus roundtable. This roundtable is sponsored by The National Keratoconus Foundation. AAO is a great meeting to discuss KC contact lens options as a group. The experts (Dr. Gelles) chosen will offer opinions, practice tips and insights from their experience managing patients with keratoconus.
American Academy of Ophthalmology – webinar
August 10, 2017
Dr. Peter S. Hersh, along with Dr. William B. Trattler, presented a live webinar for the American Academy of Ophthalmology on Corneal Collagen Crosslinking. The goals were to gain an understanding of the background and development of CXL as well as determining whether CXL is the most appropriate treatment for the patient.
American Academy of Ophthalmology, Annual Meeting – Chicago, IL
October 15-18, 2016
Dr. Hersh was invited to participate as a speaker at the Avedro North Lecture Series at AAO. He discussed the U.S. FDA Approved Cross-Linking Keratoconus and Corneal Ectasia Data. Dr. Hersh was medical monitor of the clinical trials which led to recent FDA approval.
International Forum for Scleral Lens Research – Houston, TX
December 5, 2016
Dr. Gelles is looking forward to attending the first International Forum for Scleral Lens Research Seminar meeting.
International Congress of Scleral Contacts 2016 – Miami, FL
July 29, 2016
Dr. Gelles was invited to lecture at The International Congress of Scleral Contacts meeting this past July. During his talk, “EyePrintPRO for Bilateral Proud Grafts”, he discussed scleral lens complications, scleral lenses and corneal transplants, as well as EyePrintPRO for bilateral proud grafts when all other options failed. Dr. Gelles is among a group of less than 25 trained providers worldwide who fits patients with the EyePrintPRO device. We are excited to be able to offer this technology to our patients! To read more about EyePrintPRO – https://www.keratoconuscenter.com/site/eye-printpro.htm
First Annual Intrepid Membership Meeting – Boson, MA
June 29, 2016
Dr. John Gelles, a founding member of the Intrepid Eye Society, presented, “Combined Procedures Keratoconus and Telemedicine of Eyecare” to a group of optometrists. This covered current and future procedures for KC, current and future research at The Cornea and Laser Eye Institute, as well as the role of telemedicine in eyecare.
The Intrepid Eye Society is a diverse group of emerging thought leaders in optometry with a goal of promoting excellence and growth in our field. Their initiatives include advancement of optometry through innovative thought sharing on topics related to future medical therapeutics, diagnostics, practice development, research and development, and collaborative care and ophthalmology.
New York Academy of Optometry Meeting
June 21, 2016
Dr. John Gelles was excited to be asked to discuss Corneal Collagen Crosslinking at the NYAO meeting. The lecture was titled, “FDA Approved Corneal Collagen Cross-linking for Progressive Keratoconus: Everything You Need to Know for Successful Co-management”.
Dr. Gelles is the Director of the Specialty Contact Lens Division here at The Cornea and Laser Eye Institute – CLEI Center for Keratoconus.
The Cornea and Laser Eye Institute – CLEI Center for Keratoconus
May 25, 2016
Dr. Peter Hersh and Dr. John Gelles invited local optometrists to an educational event on Corneal Collagen Crosslinking. Corneal Collagen Crosslinking was recently FDA approved and granted to Avedro, Inc. for Photrexa Viscous, Photrexa and the KXL System. Dr. Hersh was medical monitor of the clinical trial which led to this approval. Dr. Hersh discussed FDA approval for patients with progressive keratoconus while Dr. Gelles discussed how to successfully comanage patients who are having crosslinking performed.
If you are a physician interested in future continuing educational events at The Cornea and Laser Eye Institute, please contact Stacey Lazar at email@example.com.